Cellosaurus logo
expasy logo

Cellosaurus HT1080/DR4 (CVCL_6C48)

[Text version]
Cell line name HT1080/DR4
Accession CVCL_6C48
Resource Identification Initiative To cite this cell line use: HT1080/DR4 (RRID:CVCL_6C48)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
Sequence variations
  • Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
Disease Fibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0317 (HT-1080)
Sex of cell Male
Age at sampling 35Y
Category Cancer cell line
Publications

PubMed=2896069
Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M.
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Cancer Res. 48:2793-2797(1988)

PubMed=1976136; DOI=10.1093/jnci/82.19.1553
Zwelling L.A., Slovak M.L., Doroshow J.H., Hinds M., Chan D., Parker E., Mayes J., Sie K.L., Meltzer P.S., Trent J.M.
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
J. Natl. Cancer Inst. 82:1553-1561(1990)

PubMed=1673331
Slovak M.L., Coccia M., Meltzer P.S., Trent J.M.
Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Anticancer Res. 11:423-428(1991)

Cross-references
Cell line databases/resources cancercelllines; CVCL_6C48
Encyclopedic resources Wikidata; Q54896569
Entry history
Entry creation23-Feb-2016
Last entry update19-Dec-2024
Version number16